PROJECT AEROVIA-CF1A-201

Experimental Development Framework

Program Code: SCF-CF-S6-0001

Lead Candidate: AEROVIA-CF1A-201

Candidate Class: Inhaled Neutrophil Elastase Modulator

Development Status: Experimental Validation Phase

I. STAGE 6 OBJECTIVE

Stage 6 transitions from candidate nomination into experimental validation.

Primary objectives:

1. Confirm target engagement.
2. Demonstrate disease-modifying activity.
3. Characterize PK/PD relationships.
4. Establish preliminary safety margins.
5. Generate IND-supporting evidence.

At this stage, all outputs become hypothesis-driven and require laboratory confirmation.

II. STAGE 6 DEVELOPMENT HYPOTHESIS

Primary Hypothesis

Localized pulmonary modulation of neutrophil elastase will reduce progressive airway destruction while preserving sufficient innate immune function.

Secondary Hypotheses

Reduction of elastase activity will:

• Decrease MMP activation
• Reduce ECM degradation
• Reduce inflammatory amplification
• Improve epithelial integrity
• Slow bronchiectatic progression

III. EXPERIMENTAL MODULE 1 — TARGET VALIDATION

Objective

Confirm candidate engagement with neutrophil elastase.

Assay Set

A1. Biochemical Enzyme Assay

Endpoints:

• IC50
• Ki
• Reversibility
• Selectivity

Required comparator panel:

• Proteinase 3
• Cathepsin G
• Trypsin
• Chymotrypsin

Success Criteria

IV. EXPERIMENTAL MODULE 2 — HUMAN CELL VALIDATION

Human Bronchial Epithelial Models

Cell Sources

• CF patient-derived epithelial cells
• CF airway organoids
• Air-liquid interface cultures

Endpoints

V. EXPERIMENTAL MODULE 3 — CF MICROENVIRONMENT MODELING

Co-Culture System

Components:

• CF epithelial cells
• Neutrophils
• Bacterial biofilms

Organisms:

Pseudomonas aeruginosa

Staphylococcus aureus

Objectives:

Evaluate whether elastase modulation:

• reduces tissue damage
• preserves barrier function
• maintains antimicrobial activity

VI. EXPERIMENTAL MODULE 4 — PK/PD CHARACTERIZATION

Pulmonary PK

Measurements

Pharmacodynamic Markers

Primary

• Elastase activity

Secondary

• IL-8
• MMP-9
• Neutrophil burden

Exploratory

• Extracellular vesicle signatures
• Proteomic injury markers

VII. EXPERIMENTAL MODULE 5 — SAFETY VALIDATION

Acute Toxicology

Focus Areas

• Airway irritation
• Bronchoconstriction
• Pulmonary inflammation

Repeat-Dose Toxicology

Duration

28-day exploratory study

Endpoints:

• Histopathology
• BAL fluid analysis
• Cytokine profiling
• Pulmonary function

VIII. SCF RESISTANCE & ADAPTATION MODELING

Following SCF Principle 4 — Resistance Prevention.

Risk Assessment

Risk 1

Over-suppression of host defense.

Potential consequence:

Increased infection susceptibility.

Mitigation:

Partial modulation strategy.

Risk 2

Compensatory protease activation.

Potential pathways:

• Proteinase 3
• Cathepsin G

Mitigation:

Protease network monitoring.

IX. BIOMARKER QUALIFICATION PACKAGE

Tier 1 Biomarkers

Tier 2 Biomarkers

Tier 3 Biomarkers

Omics-based exploratory markers:

• Proteomics
• Metabolomics
• Transcriptomics

Aligned with the SCF multi-omics pathophysiology framework.

X. CMC EXECUTION PACKAGE

Drug Substance

Required Deliverables

Chemistry

• Synthetic route confirmation
• Impurity profiling
• Stability testing

Formulation

Primary:

Dry Powder Inhalation (DPI)

Backup:

Nebulized liposomal formulation

Manufacturing Readiness

Stage 6 Milestones

XI. PRECLINICAL SUCCESS CRITERIA

Biological Activity

Required:

≥50% reduction in elastase activity versus control.

Safety

Required:

No clinically meaningful pulmonary toxicity.

PK

Required:

Therapeutically relevant lung exposure.

Translational Readiness

Required:

Biomarker-response relationship established.

XII. STAGE 6 DECISION MATRIX

XIII. STAGE 6 EXPECTED OUTCOMES

Scenario A — Success

Candidate advances into:

Stage 7

GLP Toxicology & IND Preparation

Scenario B — Partial Success

Optimization cycle initiated:

• chemistry refinement
• formulation refinement
• dose refinement

Scenario C — Failure

Program redirected to:

• Anti-Biofilm Platform (AEROVIA-CF1A-101)
• Combination Program
• Alternative target selection

XIV. REGULATORY READINESS ASSESSMENT

At completion of Stage 6, the program should possess:

Pharmacology Package

• Target validation
• Mechanistic confirmation

Toxicology Package

• Exploratory safety profile

CMC Package

• Candidate manufacturing strategy

Clinical Translation Package

• Biomarkers
• Patient selection strategy
• Initial dose projection

These elements collectively support progression toward IND-enabling development.

STAGE 6 OUTCOME

CONDITIONAL ADVANCEMENT TARGET

STAGE 7 — GLP TOXICOLOGY, GMP MANUFACTURING & IND ASSEMBLY

Advancement requires successful completion of:

1. Target validation
2. PK/PD characterization
3. Exploratory toxicology
4. Manufacturing feasibility
5. Biomarker qualification

No clinical testing should be contemplated until these preclinical gates are successfully completed.

MASTER REGISTRY INDEX

SCF-CF-S6-0001 — Preclinical Execution & Candidate Validation

SCF-CF-AEROVIA-201 — Lead Candidate Validation Program

SCF-PKPD-0001 — Pharmacokinetic & Pharmacodynamic Framework

SCF-CMC-0001 — Manufacturing Development Framework

SCF-PATH-UT-0001 — SCF Pathophysiology Protocol

SCF-SEF-MD-0001 — Synergistic Evaluation Framework

SCF-FDA-IND-0001 — IND Development Framework

SCF-PCR-0001 — Preventative–Curative–Restorative Architecture